Abstract
Key Points: Military servicemembers reported high satisfaction rates of dupilumab treatment for CRSwNP. Some service members fear that dupilumab treatment may limit their career progression. Updated guidelines are needed for servicemembers to make decisions regarding dupilumab.
Original language | English |
---|---|
Pages (from-to) | 999-1001 |
Number of pages | 3 |
Journal | International Forum of Allergy and Rhinology |
Volume | 14 |
Issue number | 5 |
DOIs | |
State | Accepted/In press - 2023 |
Keywords
- chronic rhinosinusitis
- immunotherapy
- quality of life